



Current and Investigational Therapies Used to Alter the Course of Disease in Multiple Sclerosis

AARON MILLER, MD, Brooklyn, NY

ABSTRACT: Extensive research is under way to develop pharmacotherapeutic agents that will prevent the exacerbations and the progression of neurologic disability associated with multiple sclerosis (MS). The most intensive research strategy has involved agents intended to limit demyelination by reducing inflammation and modifying the immune response. In this category are interferon beta-1b, the first compound approved for use outside of clinical trials; interferon beta-1a; and copolymer 1. Experimental agents include other interferons, methotrexate, linomide, monoclonal antibodies, T-cell receptor peptides, and 2-chlorodeoxyadenosine. Although they have been used effectively to treat exacerbations of MS, corticosteroids and corticotropin are now under evaluation as disease-modifying agents. A second strategy, enhancing remyelination by limiting demyelination and oligodendrocyte injury, is represented by protein growth factors. A third therapeutic approach, improving conduction in demyelinated fibers, is represented by the potassium channel blockers 4-aminopyridine and 3,4-diaminopyridine.

MULTIPLE SCLEROSIS (MS) is a demyelinating disease of the central nervous system that is marked by focal or multifocal destruction of myelin sheaths accompanied by inflammation. Limited axonal destruction may also occur. Clinically, MS is characterized by recurrent attacks of neurologic dysfunction.

From a pathophysiologic standpoint, MS can be identified by the presence of diffuse, discrete demyelinated areas, called plaques. As the disease progresses, plaques increasingly arise in the paraventricular areas of the cerebrum, in the subpial area, and within the brain stem and spinal cord. A local breakdown of the blood-brain barrier occurs in areas of active lesions.¹

Although the etiology of MS remains unknown, epidemiologic studies suggest that both environmental and genetic factors play a role.² MS is now widely viewed as an autoimmune disease that develops early in life in the

genetically susceptible person, perhaps after a viral infection initiates a T-cell-mediated immune response.³

Multiple sclerosis is usually classified according to one of four recently standardized clinical courses: relapsing-remitting, primary-progressive, secondary-progressive, or progressive-relapsing.⁴ In the relapsing-remitting form, which accounts for two thirds of cases at the onset of the disease, attacks occur randomly over many years.⁵ The extent of recovery among patients and from attack to attack is variable, but permanent deficits can accrue with each exacerbation, especially later in the course of the disease.^{5,7} This neurologic deterioration, which may still be punctuated by intermittent acute attacks, is classified as secondary-progressive, as opposed to primary-progressive, and progressive-relapsing. These forms are progressive from the onset.⁴

EVALUATION OF DISEASE BURDEN

Depending on the location of the lesions, signs and symptoms of MS may include vision disturbances, nystagmus, dysarthria, diminished perception of vibration and position sense, ataxia and intention tremor, weakness or paralysis of one or more limbs, spasticity,

From the Division of Neurology, Maimonides Medical Center, Brooklyn, NY; and the Department of Neurology, State University of New York Health Science Center at Brooklyn.

Supported by an unrestricted educational grant from Berlex Laboratories, Richmond, Calif.

Reprint requests to Aaron Miller, MD, Division of Neurology, Maimonides Medical Center, 4802 Tenth Ave, Brooklyn, NY 11219.



and bladder disorders. Neurologic abnormalities that are highly suggestive of MS are optic neuritis, internuclear ophthalmoplegia, and Lhermitte's sign, which is often described as an electrical sensation that passes down the back and into the legs when the neck is flexed.⁸

Disability attributable to MS is usually measured by the Expanded Disability Status Scale (EDSS) developed by Kurtzke.⁹ This system uses findings from a standard neurologic examination to establish a functional status score. Functional systems scores and gait then guide the evaluator in assessing clinical impairment with the EDSS, which defines disability in half-point increments ranging from 0 (normal neurologic findings) to 10 (death due to MS).

Magnetic resonance imaging (MRI) provides the most accurate assessment of disease burden, identifying multifocal cerebral white matter lesions in more than 90% of people with MS.² Even when there are no clinical signs, serial MRI studies of patients with relapsing-remitting MS can identify developing lesions.² In fact, it is now well established that new lesions as identified by MRI occur 5 to 10 times more often than clinical changes.¹⁰ Recent refinements in MRI, such as gadolinium enhancement, magnetization transfer, and magnetic resonance spectroscopy, have improved the sensitivity of detecting MS-associated lesions.¹¹

TREATMENT OF MULTIPLE SCLEROSIS

Current therapy for MS includes relief of symptoms, amelioration of exacerbations, and reduction in the number of exacerbations and subsequent progression of neurologic disability. Symptomatic treatment addresses both the physical and psychologic needs of the patient. It includes pharmacotherapy, diet, energy conservation, physical therapy, patient and family counseling, support groups, mechanical devices, and surgery.^{12,13} Exacerbations are usually treated with corticosteroids or corticotropin (ACTH), and administration of high doses of intravenous methylprednisolone (IVMP) has become particularly widely used.¹³

The third area of MS therapy, preventing exacerbations and progression of neurologic disability associated with the disease, has stimulated various approaches. These can be grouped into three major categories: limiting demyelination by reducing inflammation and regulating the immune response, enhancing

remyelination by limiting demyelination and oligodendrocyte injury, and improving conduction in demyelinated fibers.³ The remainder of this review discusses each of these therapeutic strategies and the specific treatments that have been developed, or are in development, in response to each approach.

EFFORTS TO LIMIT DEMYELINATION

Most pharmacologic treatments aimed at reducing or preventing exacerbations of MS and associated neurologic disability fall into the category of limiting demyelination by reducing inflammation and suppressing the immune response.³

Interferon beta

The first agent shown to alter the natural course of MS by reducing the frequency of clinical exacerbations is interferon beta-1b (IFN β -1b [Betaseron]), a recombinant interferon-beta produced in *Escherichia coli*. IFN β -1b differs from natural interferon- β in that it is not glycosylated and has serine substituted for the cysteine residue at amino acid position 17. It is indicated for use in ambulatory patients with relapsing-remitting MS to reduce the frequency of clinical exacerbations.¹⁴ Although the overall mechanisms by which IFN β -1b exerts its actions are unknown, it is believed to bind to the same cell surface receptor as interferon-alpha and natural interferon- β .¹⁵ It induces the expression of a number of proteins, via transcription factors, that mediate its immunologic, antiproliferative, and antiviral effects.¹⁶ The immunomodulatory effects of IFN β -1b are believed to play the major role in reducing the number and frequency of exacerbations in patients with MS.^{16,17}

A double-blind, randomized, placebo-controlled, multicenter phase III trial was conducted in which 372 patients with relapsing-remitting MS received placebo (n = 123) or either 1.6 million IU (n = 125) or 8 million IU (n = 124) of IFN β -1b subcutaneously, every other day, for 2 years.^{18,19} Eligibility criteria included clinically evident MS of at least 1 year's duration and at least two exacerbations in the 2 years preceding the trial without an exacerbation in the preceding month. Other inclusion criteria were an EDSS score of 5.5 or less (ambulatory without aids) and clinically stable disease at study entry. Patients who had received previous immunosuppressant therapy were excluded, and those needing more than



three brief courses of corticosteroids during a 12-month period were withdrawn from the study. At the end of 2 years, 80% of patients remaining in the study elected to continue treatment under double-blind conditions. Some patients were treated for as long as 5½ years.

After 2 years of treatment, the annual exacerbation rates in patients who received placebo or 1.6 million or 8 million IU IFNβ-1b were 1.27, 1.17, and 0.84 per year, respectively. The lower rate in the group given 8 million IU represents a 34% decrease from the placebo exacerbation rate and is highly significant ($P = .0001$). After 3 years, the exacerbation rate in the high-dose group (0.84) compared with that in the placebo group (1.21) was still significantly reduced ($P = .0004$).¹⁸

There was also a significant difference in the proportion of exacerbation-free patients among the treatment groups. After 2 years, the percentage of patients without exacerbations in the 8 million IU IFNβ-1b group (31%) was almost twice that in the placebo group (16%) ($P = .007$). At 3 years, 22% of patients in the high-dose group were exacerbation free, compared with 14% in the placebo group, but the difference was no longer statistically significant ($P = .097$).¹⁸

Serial annual MRIs showed no significant progression in lesion burden in the 8 million IU IFNβ-1b group in each successive year, whereas there was a highly significant increase in lesion area in the placebo group ($P = .0001$).¹⁹

Of the 124 patients who received IFNβ-1b therapy at the recommended dose of 8 million IU every other day during clinical trials, 76% reported a flu-like symptom complex.¹⁴ Over 3 years, the incidence of these events declined, with only 4% of patients experiencing the complex during the last 6 months. Other common adverse clinical and laboratory events associated with IFNβ-1b therapy include injection site reactions and menstrual disorders. The former are generally mild, but in approximately 5% of patients, skin necrosis may occur. This has occasionally required surgical treatment. Absolute neutrophil count less than 1,500/mm³, white blood cell count less than 3,000/mm³, and AST and ALT levels greater than 5 times baseline value may occur on occasion.¹⁴ Neutralizing antibodies to IFNβ-1b developed in 27% of patients in the 8 million IU group in year 1, 6% of patients in year

2, and 2% in year 3; antibody positivity, which was sporadic in some patients and sustained in others, was associated with an increased exacerbation rate comparable to that in the placebo group.¹⁹

The approval of IFNβ-1b has had a noticeable effect on patients with MS and their families, neurologists, and clinical investigators and has brought about a new sense of therapeutic optimism.²⁰

A second recombinant interferon-β, IFNβ-1a (Avonex), a natural sequence, glycosylated IFN-β produced in Chinese hamster ovary cells, is now marketed for the treatment of relapsing MS. IFNβ-1a also has been tested in a phase III randomized, placebo-controlled, double-blind multicenter trial, in which 301 patients received placebo ($n = 143$) or 6 million IU IFNβ-1a ($n = 158$) intramuscularly, once a week for 2 years.²¹ In contrast to the IFNβ-1b phase III trial, the primary outcome measure in the IFNβ-1a trial was progression of disability rather than exacerbation rate. Progression of disability was measured by the time taken for an increase to occur in the EDSS score of 1.0 unit above baseline persisting for at least 6 months. Secondary outcome measures included time to first exacerbation, exacerbation rate, proportion of patients remaining exacerbation free, and change in disease burden as measured by MRI.²¹

Time to sustained progression of disability was significantly greater in the IFNβ-1a group than in the placebo group ($P = .02$).²¹ The proportion of patients with progression of disability at 2 years was 21.9% in the IFNβ-1a group compared with 34.9% in the placebo group.²¹ In addition, patients receiving IFNβ-1a had one third fewer exacerbations and a significant reduction in the number of lesions as detected by gadolinium (Gd)-enhanced MRI, as compared with placebo.²¹⁻²³

As in the IFNβ-1b clinical trial, the most frequent adverse effects in patients receiving IFNβ-1a were flu-like symptoms, injection site reactions, and menstrual disorders. However, in contrast to IFNβ-1b, local skin irritation and necrosis do not occur. Serum neutralizing anti-IFN activity was observed in 14% of patients receiving IFNβ-1a at week 52, in 21% of patients at week 78, and in 22% of patients at week 104; the majority of patients remained positive for neutralizing activity on repeat testing.²¹ It is not yet clear whether this will affect clinical efficacy.



Other Interferons

Early clinical trials of both natural and recombinant IFN- α in patients with MS were not too promising.¹⁷ This is surprising, since both IFN- β and IFN- α bind to the same cell surface receptor and have similar immunoregulatory functions.¹⁶ It is possible that the relatively small doses and the frequency and route of administration used in the early trials were suboptimal. A recent 6-month randomized, double-blind, placebo-controlled pilot trial involving 20 patients with relapsing-remitting MS had more promising results.²⁴ Patients receiving 9 million IU of IFN α -2a (Roferon-A) intramuscularly every other day for 6 months had a significant reduction in exacerbation rate ($P < .03$), and a higher proportion remained exacerbation free ($P < .02$) compared with the placebo group. In addition, the median time to first exacerbation was approximately twice as long in the IFN α -2a group as in the placebo group (111 days versus 58 days).²⁴ MRI studies done before and after treatment revealed only one active lesion in the IFN α -2a group compared with 27 lesions in the placebo group—a significant difference ($P < .01$). Thus, the MRI data verified the clinical information regarding the benefits of IFN α -2a treatment.²⁴

As with all interferon compounds, IFN α -2a caused moderate side effects, mainly a flu-like complex and some mild laboratory abnormalities similar to those observed with IFN β -1a and IFN β -1b.^{19,21,24} IFN- γ has also been tested in clinical trials of MS, but it causes significant increases in disease activity.¹⁷

Corticosteroids and Corticotropin

These compounds are thought to exert their beneficial effect in MS by reducing abnormalities in the blood-brain barrier, decreasing edema, improving axonal conduction, reducing intrathecal immunoglobulin G synthesis, and inducing immunosuppression by the steroid-mediated blockade of cytokine gene expression.²⁰ Despite their established role in managing exacerbations of MS, the use of corticosteroids and corticotropin (ACTH) to prevent acute attacks and favorably alter disease progression has not been thoroughly investigated.²⁰ Early trials showed that neither low doses of oral prednisolone²⁵ nor intramuscular ACTH²⁶ had any benefits after 18 months of treatment when compared with placebo.

In one study, Compston and colleagues²⁷ concluded that a short course of high-dose

IVMP, frequently used to treat the exacerbations of MS, did not have a prolonged effect on the immunologic abnormalities associated with the disease and thus had no long-term therapeutic value in patients with relapsing-remitting or chronic-progressive MS.

However, a recent study by the Optic Neuritis Study Group to evaluate the effect of corticosteroid therapy on the development of definite MS in patients treated for optic neuritis, often the first manifestation of MS, had a positive outcome.²⁸ Within 2 years, definite MS developed in 7.5% of patients treated with 1,000 mg of IVMP for 3 days and in 16.7% of those in the placebo group, a statistically significant difference ($P = .006$).²⁸ Interestingly, the beneficial effect of IVMP occurred most in patients at greatest risk for developing clinically definite MS, as judged by the multifocal lesions seen on their MRI scans.²⁸ This study may encourage clinicians to administer IVMP for the first episode of optic neuritis, or any other neurologic abnormality that might signal the onset of MS, in an attempt to favorably alter the course of the disease.²⁹ In patients whose MS has progressed further, corticosteroids may be most valuable when they are used in conjunction with other immunologic agents.²⁷ In patients with progressive MS, IVMP did not seem to affect the natural progression of the disease.³⁰

In addition to this study, a 2-year clinical trial comparing the relative benefits of bimonthly pulses of 10 mg versus 500 mg of IVMP is now in progress, and a separate study comparing the benefits of IVMP and IFN β -1b is being planned.²⁰ There is evidence from one study³⁰ that 1,000 mg of IVMP daily for 10 consecutive days significantly reduced the relapse rate over an average of 2.6 years in patients with relapsing-remitting or progressive-relapsing MS (compared with rates 1 year before study entry [$P < .0001$]).

Azathioprine

Azathioprine, a purine analogue that suppresses cell-mediated hypersensitivity reactions and alters antibody production,²⁰ has been used in clinical trials of patients with MS. Results of 22 such trials have been published.²⁰ Seven of these, two single-blind and five double-blind studies, were reviewed in a meta-analysis by Yudkin et al.³¹ This analysis evaluated data from 793 patients with relapsing-remitting, progressive, or progressive-relapsing MS, 459 of whom had been treated for at least 3 years.³¹ Mean



changes in Kurtzke disability scores, reported in six of the trials, indicated increased neurologic impairment after 1, 2, and 3 years; although the degree of neurologic impairment was less than that observed in the control groups, it was not statistically significant.³¹ Azathioprine significantly reduced the risk of relapse, and the probability of remaining disease free was 1.51, 2.04, and 1.97 times greater after 1, 2, and 3 years, respectively. However, adverse effects were common in treated patients and included leukopenia, anorexia, diarrhea, vomiting, abdominal pain and other gastrointestinal disturbances, abnormal liver function, and skin rash.³¹ Despite lingering concerns that cancer may develop after long-term administration, this association has not been substantiated.³²

Although azathioprine remains an investigational agent for the treatment of MS and its clinical benefit appears to be modest, it is the most commonly used form of immunosuppressant therapy for this disease.²⁰ It is probable that azathioprine will continue to have a limited role in the management of patients with MS because of its relatively acceptable toxicity, favorable cost, and comparative ease of administration.²⁰

Cyclophosphamide

Administration of cyclophosphamide, an alkylating agent with cytotoxic as well as immunosuppressive effects, reduces the numbers of helper T cells and suppressor T cells. This reduction is more pronounced in the former.²⁰

Many trials have confirmed that the clinical benefits of cyclophosphamide therapy for MS are restricted to the short term and are marginal at best, with toxicity being a major problem.²⁰ Acute toxicity includes nausea and vomiting, alopecia, hemorrhagic cystitis, and myelosuppression, whereas long-term toxicity may involve induction of leukemia or bladder cancer. Accordingly, cyclophosphamide is an unlikely candidate for long-term therapy for patients with MS.^{33,34} However, a recent study in which patients with MS were given pulse IV cyclophosphamide therapy in combination with monthly IVMP suggested a clinical benefit due to a shift from a Th1-type to a Th2-type cytokine profile (IFN- γ , lymphotoxin versus IL-4, IL-5).³⁵

Cyclosporine

Cyclosporine (cyclosporin A), which is widely used to prevent graft rejection after

organ transplantation, is an immunosuppressive agent with a relatively specific, but reversible, inhibitory effect on helper T cells.^{7,36} Since preliminary reports have shown that cyclosporine can modify the course of experimental allergic encephalomyelitis in animals and may have value in the treatment of other autoimmune diseases in humans, its possible therapeutic role in MS has been investigated.³⁶

The Multiple Sclerosis Study Group conducted a placebo-controlled, double-blind trial of 554 patients with progressive MS in which 273 patients received a daily dose of oral cyclosporine for 2 years.³⁶ Patients in the treatment group had a statistically significant delay in disease progression, but the clinical effects of treatment were slight. Furthermore, the nephrotoxicity and hypertensive effects of the drug outweighed its benefits. Adverse effects were also a cause for concern in a multicenter, double-blind, randomized trial of cyclosporine versus azathioprine involving 194 patients, the majority of whom had relapsing-remitting MS.³⁷ No significant differences in exacerbation rates or disability progression were shown over 2 years, and more than twice as many side effects were reported in the cyclosporine group as in the azathioprine group.

Methotrexate

Because of its anti-inflammatory and immunomodulatory actions, in addition to its beneficial effect in rheumatoid arthritis, another autoimmune disease, methotrexate is now under investigation for the treatment of progressive MS.³⁸ In a double-blind, placebo-controlled phase II study, 60 patients with an EDSS score of 3.0 to 6.5 received weekly placebo or 7.5 mg of oral methotrexate. A composite of outcome measures reflecting both upper and lower extremity function was used to measure efficacy of treatment. At the end of the 2-year study period, progression of neurologic impairment was significantly less in the group given methotrexate ($P = .011$), and adverse effects were minimal.³⁸

Roquinimex

The synthetic immunomodulator roquinimex (Linomide) has shown promise in patients with relapsing-progressive MS. Roquinimex increases natural killer cell activity and stimulates other lymphocyte subpopulations.³⁹ It also interferes with antigen presen-



tation, inhibiting T-cell activation early enough so that induction of generalized immunosuppression does not occur.³⁹ Because roquinimex was extremely effective in limiting the clinical and pathologic signs of experimental allergic encephalomyelitis in mice, a recent double-blind, placebo-controlled study involving 30 patients with relapsing-progressive MS (EDSS scores of 3.0 to 7.0) was done. Patients received either 2.5 mg of roquinimex per day or placebo orally and had follow-up for 6 to 12 months, with monthly T1 Gd-enhanced and T2 MRI. Initial reports showed that after 6 months of treatment, patients receiving roquinimex had a significant favorable change in their EDSS score ($P < .036$) and significantly fewer new enhancing lesions ($P < .021$) than patients who received placebo. Side effects were mild and included myalgia, arthralgia, and edema.³⁹ A large, multicenter phase III trial in patients with progressive MS was begun in 1996.

Copolymer 1

Copolymer 1 (COP 1, Copaxone) is a synthetic polypeptide composed of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, amino acids commonly found in myelin basic protein (MBP).⁴⁰ COP 1 is a mixture of polymers, the sequence and length of which vary randomly. It was originally developed as an MBP analogue, and like MBP itself, COP 1 inhibits experimental allergic encephalomyelitis in several mammalian species.

In a double-blind, placebo-controlled pilot trial, 50 patients with relapsing-remitting MS self-injected 20 mg of COP 1 or placebo subcutaneously daily for 2 years. Over the 2 years, an average of 2.7 exacerbations occurred per patient in the placebo group and an average of 0.6 in the COP 1 group.⁴¹

COP 1 has recently been under evaluation in an 11-center, phase III double-blind clinical trial in the United States, involving 251 patients with relapsing-remitting MS. Results indicate a significant reduction of 29% in the exacerbation rate over the 2 years of study in the COP 1-treated patients compared with that in the placebo-treated patients ($P = .007$).⁴² The median time to first relapse was longer in COP 1-treated patients (287 days) than in placebo-treated patients (198 days), and the percentage of COP 1-treated patients remaining exacerbation free was higher than that of placebo-treated patients (33.6% vs 27.0%); these last results approached statistical significance.⁴² Like

the earlier pilot trial, the therapeutic effect of COP 1 appeared to be more pronounced in patients with minimal disability (EDSS score of 0 to 2). Also, in both trials irritation at the injection site and rare transient reactions characterized by chest tightness or flushing combined, at times, with dyspnea, palpitations, or anxiety were the only side effects noted.^{41,42}

Monoclonal Antibodies

The use of lymphocytotoxic monoclonal antibodies against specific T-cell subpopulations in patients with MS is another promising avenue of therapy. Two types of monoclonal antibody are under investigation: humanized and chimeric. In humanized monoclonal antibodies, only the complementary determining regions (also known as hypervariable regions) are nonhuman; in chimeric monoclonal antibodies, the complete Fab portion is nonhuman and has been fused onto a human Fc portion.⁴³ It is believed that these antibodies will be less immunogenic than complete mouse monoclonal antibodies and thus can be used repeatedly in patients to reduce the activity of specific lymphocyte populations. In preliminary studies using the humanized antibody CAMPATH-1H, which is directed against the lymphocyte surface antigen CDw52,⁴⁴ seven ambulatory patients with chronic-progressive MS had rapid and profound lymphopenia.⁴³ Gadolinium-enhanced MRI showed a substantial reduction in new lesion formation, although some active lesions found at the start of treatment continued to develop for approximately 3 months. Several patients had transient but marked neurologic changes, including deterioration in vision, inability to walk, and bilateral internuclear ophthalmoplegia. These temporary effects were attributable to substantially increased levels of circulating tumor necrosis factor- α , interferon- γ , and interleukin-6; values returned to normal within 18 hours.

The potentially hazardous effects of CAMPATH-1H on the immune system indicate that this particular form of monoclonal antibody therapy should be regarded only as a clinical experiment.⁴³ However, it is likely that investigation of monoclonal antibody therapy for MS will continue.⁴³

T-Cell Receptor Peptides

Studies in rodents have shown that vaccination with attenuated encephalitogenic T cells specific for MBP induces cell-mediated protec-



tion against experimental allergic encephalomyelitis. Moreover, experimental allergic encephalomyelitis can be treated and prevented by vaccination of the animals with certain peptides from the antigen-recognizing portion of T-cell receptors (TCRs) expressed by MBP-specific T cells.⁴⁵

These results have led to a recently reported double-blind, placebo-controlled pilot study to evaluate the clinical and immunologic effects of TCR peptide vaccination in 23 patients with progressive MS. A native peptide ($n = 8$) with the V β 5.2 sequence expressed in MS plaques and on MBP-specific T cells and a substituted peptide ($n = 9$) were tested. Treatment consisted of 100 μ g of peptide or placebo administered weekly for 4 weeks, then monthly for an additional 10 months, by intradermal injection. Response to vaccination, defined as increased frequency of TCR peptide-reactive T cells, was accompanied by decreased frequency of MBP-specific T cells ($P < .001$); 6 of the 17 peptide recipients responded to vaccination, 1 in response to the native peptide and 5 in response to the substituted peptide. All 6 vaccine responders remained clinically stable or showed improvement over the course of the trial, without any reported side effects; in contrast, 10 of the 17 nonresponders receiving either peptide or placebo progressed clinically ($P = .019$). Further study of the TCR peptide vaccination approach and development of more sensitive techniques may enable more widespread application to MS as well as other tissue-specific autoimmune diseases involving T cells.⁴⁵

Cladribine

The highly specific antilymphocyte/antimonocyte immunosuppressive nucleoside, cladribine (2-chlorodeoxyadenosine [2-CdA]), has been shown in preliminary investigations to have potential value in altering the clinical course of chronic-progressive MS.⁴⁶ In a double-blind, placebo-controlled study, 49 patients received 7-day infusions of 2-CdA (0.1 mg/kg) or saline infusions monthly for 4 months. After 1 year, there was a significant difference in the mean change in EDSS scores between the two groups ($P = .003$). As measured by MRI, total lesion burden after 1 year was also significantly less in the 2-CdA group than in the placebo group ($P = .003$).⁴⁶ After 2 years, the number of active lesions was markedly reduced in the 2-CdA group to almost zero.⁴⁷ Bone marrow suppression was observed in

some patients who received 2-CdA, and significant thrombocytopenia developed in a few. Two cases of herpes zoster also occurred in the cladribine group.⁴⁶

NONPHARMACOLOGIC INTERVENTIONS

Although this review focuses on pharmacotherapy, several nonpharmacologic treatments intended to limit demyelination have also been investigated and are noted briefly here.

Total lymphoid irradiation (TLI), generally considered a relatively safe method for achieving sustained immunosuppression, temporarily interrupted disease progression in patients with progressive MS, but deterioration resumed at a median of 3 years after treatment.⁴⁸

A recent study suggests that TLI in combination with low-dose prednisone may inhibit the rate of disease progression in patients with progressive MS, since there was a significant difference in EDSS scores between patients receiving the active treatment and those receiving placebo ($P < .005$).⁴⁹

Plasmapheresis done in conjunction with immunosuppressive therapy has been used with some success to treat patients with MS, although the beneficial effects were limited to less than 1 year.⁵⁰ The results could not be replicated in a Canadian study.³³

EFFORTS TO ENHANCE REMYELINATION

Although it is not yet known whether remyelination can be promoted in humans with MS, this approach is being actively investigated.³ Histologic studies show that remyelination occurs in the early postinflammatory lesion but that most or all areas of inflammation eventually mature into demyelinated areas in which oligodendrocytes have been lost. This is probably due to a recurrence in inflammation.⁴³ For the most part, axons are unaffected by this destructive process.⁵¹ When natural remyelination does occur, the remyelinating cell is a glial precursor. Unlike a mature oligodendrocyte, these progenitor cells retain their ability to proliferate, migrate, survive, and differentiate.⁴³

One potential approach to remyelination is transplantation of purified oligodendrocyte-type-2-astrocyte progenitor cells into the demyelinated areas. This has been done experimentally in rats.⁵² Progenitor cells, obtained from optic nerves of 7-day-old rats and grown in culture in the presence of basic fibroblast growth factor (bFGF) and platelet-



derived growth factor (PDGF), were transplanted into demyelinating lesions in the spinal cord of adult rats. Three weeks after transplantation, microscopic examination of the treated areas showed clear evidence of remyelination in 8 of 10 animals. Although this study indicates that large populations of cells that are suitable for transplantation can be produced, it remains to be determined whether the remyelinated axon will function normally.⁵²

In light of this and related studies, some argue that sufficient data now exist to support the intracranial administration of PDGF and bFGF in laboratory animals with experimentally induced chronic demyelinating disorders. It is believed that this will lead to the development of protein growth factor-based treatments to repair lesions in patients with MS.⁵³

EFFORTS TO IMPROVE CONDUCTION IN DEMYELINATED FIBERS

It is possible that demyelinated axons in MS lesions may be capable of conducting impulses.⁵⁴ Studies have shown that the conduction block in demyelinated fibers is partly due to the appearance of aminopyridine-sensitive potassium channels in demyelinated areas.⁵⁵ Preclinical studies using the potassium channel blockers 4-aminopyridine (4-AP) and 3,4-diaminopyridine (DAP) resulted in improved conduction in experimentally demyelinated nerves and thus warrants clinical trials in patients with MS.⁵⁴

Many trials, reviewed by Bever,⁵⁴ have shown that 4-AP and DAP can improve neurologic function in MS patients, as measured by vision testing, neurologic examination, or EDSS, and so may be beneficial in the symptomatic treatment of MS. One study suggests that approximately 30% of MS patients are likely to have a significant clinical response at the outset of 4-AP therapy and that 80% to 90% of these patients will continue to benefit during long-term administration.⁵⁶

A potential obstacle to the therapeutic use of 4-AP and DAP is their safety profile. Although paresthesia, gait instability, dizziness, and abdominal pain have been reported, the most serious concern is seizures.⁵⁴ Seizures have rarely occurred at the doses used in MS trials, but they occur commonly at higher doses and have been reported in patients receiving doses as low as 100 mg per day of DAP and 50 mg per day of 4-AP.

CONCLUSION

It appears likely that intensive and diverse efforts will continue to be directed toward the development of therapies to prevent the exacerbations and progression of neurologic disability associated with MS. At the level of basic research, possible participants involved in myelin destruction, such as tumor necrosis factor- α and other cytokines, will probably receive attention. Investigations of new immunosuppressive therapies will continue the quest for efficacious agents with greater selectivity and thus a better safety profile.

Because monoclonal antibody therapy offers a means of achieving rapid and substantial anti-inflammatory effects, new agents with a more favorable safety profile than CAMPATH-1H will almost certainly be investigated. Evaluation of the use of protein growth factors to enhance remyelination is likely to intensify.^{3,43,53}

With respect to IFN β -1a and IFN β -1b, currently the only approved medications shown to favorably alter the course of MS, the development of biologic products that may enhance this effect in patients with relapsing-remitting MS will be explored.²⁰ The finding that there is a synergistic effect between IFN- β and COP 1 in controlling MBP-active T cells in vitro suggests one promising avenue of approach.⁴⁰

References

1. Bastianello S, Pozzilli C, Bernardi S, et al: Serial study of gadolinium-DPTA MRI enhancement in multiple sclerosis. *Neurology* 1990; 40:591-595
2. Antel JP, Arnason BGW: Demyelinating diseases. *Harrison's Principles of Internal Medicine*. Wilson JD, Braunwald E, Isselbacher KJ, et al (eds). New York, McGraw-Hill, 12th Ed, 1991, pp 2038-2045
3. Whitaker JN: Rationale for immunotherapy in multiple sclerosis. *Ann Neurol* 1994; 36(suppl):S103-S107
4. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. *Neurology* 1996; 46:907-911
5. Weinshenker BG, Bass B, Rice GPA, et al: The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. *Brain* 1989; 112:133-146
6. Connelly JF: Interferon beta for multiple sclerosis. *Ann Pharmacother* 1994; 28:610-616
7. Weiner HL, Hafler DA: Immunotherapy of multiple sclerosis. *Ann Neurol* 1988; 23:211-222
8. Cutler RW: Demyelinating disease. *Scientific American Medicine: Neurology*. Rubenstein E, Federman DD (eds). New York, Scientific American, 1987, pp 1-5
9. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983; 33:1444-1452
10. Miller DH: Magnetic resonance in monitoring the treatment of multiple sclerosis. *Ann Neurol* 1994; 36(suppl):S91-S94
11. Husted C: Contributions of neuroimaging to diagnosis and monitoring of multiple sclerosis. *Curr Opin Neurol* 1994; 7:234-241



12. Noseworthy JH: Review: therapeutics of multiple sclerosis. *Clin Neuropharmacol* 1991; 14:49-61
13. Matthews WB: Treatment. *McAlpine's Multiple Sclerosis*. Matthews WB (ed). New York, Churchill-Livingstone, 2nd Ed, 1991, pp 251-298
14. *Physician's Desk Reference*. Montvale, NJ, Medical Economics Data Production Co, 50th Ed, 1996, pp 658-663
15. Arnason BGW, Reder AT: Interferons and multiple sclerosis. *Clin Neuropharmacol* 1994; 17:495-547
16. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al: The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. *Ann Neurol* 1995; 37:7-15
17. Panitch HS: Interferons in multiple sclerosis: a review of the evidence. *Drugs* 1992; 44:946-962
18. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology* 1993; 43:655-661
19. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. *Neurology* 1995; 45:1277-1285
20. Goodkin DE: Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. *West J Med* 1994; 161:292-298
21. Jacobs LD, Cookfair DL, Rudick RA, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. *Ann Neurol* 1996; 39:285-294
22. Investigators report on new MS drug (Special Report). *MS Quarterly Report* 1994; 13:1-2
23. Simon JH, Jacobs L, Cookfair D, et al: The natural history of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon beta-1a (Abstract). *Neurology* 1995; 45(suppl 4):A418
24. Durelli L, Bongioanni MR, Cavallo R, et al: Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. *Neurology* 1994; 44:406-413
25. Miller H, Newell DJ, Ridley A: Multiple sclerosis: trials of maintenance treatment with prednisolone and soluble aspirin. *Lancet* 1961; 1:127-129
26. Millar JHD, Vas CJ, Noronha MJ, et al: Long-term treatment of multiple sclerosis with corticotrophin. *Lancet* 1967; 2:429-431
27. Compston DAS, Milligan NM, Hughes PJ, et al: A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: II. Laboratory results. *J Neurol Neurosurg Psychiatry* 1987; 50:517-522
28. Beck RW, Cleary PA, Trobe JD, et al: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. *N Engl J Med* 1993; 329:1764-1769
29. Kupersmith MJ, Kaufman D, Paty DW, et al: Megadose corticosteroids in multiple sclerosis (Editorial). *Neurology* 1994; 44:1-4
30. Frequin STFM, Lamers KJB, Barkhof F, et al: Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. *Acta Neurol Scand* 1994; 90:105-110
31. Yudkin PL, Ellison GW, Ghezzi A, et al: Overview of azathioprine treatment in multiple sclerosis. *Lancet* 1991; 338:1051-1055
32. Goodkin DE, Bailly RC, Teetzen ML, et al: The efficacy of azathioprine in relapsing-remitting multiple sclerosis. *Neurology* 1991; 41:20-25
33. The Canadian Cooperative Multiple Sclerosis Study Group: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. *Lancet* 1991; 337:441-446
34. Noseworthy JH, Ebers GC, Roberts R: Cyclophosphamide and MS (Letter). *Neurology* 1994; 44:579-581
35. Smith DR, Balochov KE, Hafler DA, et al: Pulse intravenous cyclophosphamide therapy induces a shift from a Th1- to a Th2-type cytokine profile in multiple sclerosis patients (Abstract). *Neurology* 1995; 45(suppl 4):A213
36. The Multiple Sclerosis Study Group: Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. *Ann Neurol* 1990; 27:591-605
37. Kappos L, Patzold U, Doimasch D, et al: Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. *Ann Neurol* 1988; 23:56-63
38. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. *Ann Neurol* 1995; 37:30-40
39. Karussis D, Meiner Z, Lehmann D, et al: Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: results of a double-blind placebo-controlled study with monthly MRI evaluation (Abstract). *Neurology* 1995; 45(suppl 4):A417
40. Johnson KP: Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. *Ann Neurol* 1994; 36(suppl):S115-S117
41. Bornstein MB, Miller A, Slagle S, et al: A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. *N Engl J Med* 1987; 317:408-414
42. Johnson KP, Brooks BR, Cohen JA, et al: Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. *Neurology* 1995; 45:1268-1276
43. Compston A: Future prospects for the management of multiple sclerosis. *Ann Neurol* 1994; 36(suppl):S146-S150
44. Hale G, Xia M-Q, Tighe HP, et al: The CAMPATH-1 antigen (CDw52). *Tissue Antigens* 1990; 35:118-127
45. Vandembark AA, Chou YK, Whithan R, et al: Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. *Nature Med* 1996; 2:1109-1115
46. Sipe JC, Romine JS, Koziol JA, et al: Cladribine in the treatment of chronic progressive multiple sclerosis. *Lancet* 1994; 344:9-13
47. Sipe JC, Romine J, Koziol J, et al: Cladribine treatment of chronic progressive (C/P) MS: a double-blind, crossover study with 2+ years' observation (Abstract). *Neurology* 1995; 45(suppl 4):A418
48. Cook SD, Devereux C, Troiano R, et al: Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. *Lancet* 1986; 1:1405-1409
49. Cook SD, Bansil S, Boos J, et al: Total lymphoid irradiation (TLI) and low-dose prednisone (LDP) in progressive multiple sclerosis (PMS) (Abstract). *Neurology* 1995; 45(suppl 4):A417
50. Khatri BO, McQuillen MP, Harrington GJ, et al: Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. *Neurology* 1985; 35:312-319
51. Dijkstra CD, Polman CH, Berkenbosch F: Multiple sclerosis: some possible therapeutic opportunities. *Trends Pharmacol Sci* 1993; 14:124-129
52. Groves AK, Barnett SC, Franklin RJM, et al: Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells (Letter). *Nature* 1993; 362:453-455
53. Grinspan JB, Stern J, Franceschini B, et al: Protein growth factors as potential therapies for central nervous system demyelinating disorders. *Ann Neurol* 1994; 36(suppl):S140-S142
54. Bever CT Jr: The current status of studies of aminopyridines in patients with multiple sclerosis. *Ann Neurol* 1994; 36(suppl):S118-S121
55. Waxman SG: Membranes, myelin, and the pathophysiology of multiple sclerosis. *N Engl J Med* 1982; 306:1529-1532
56. Polman CH, Bertelsmann FW, van Loenen AC, et al: 4-Aminopyridine in the treatment of patients with multiple sclerosis. *Arch Neurol* 1994; 51:292-296